IKZF1 and plasma cell myeloma: Thalidomide and its structural analogs lenalidomide and pomalidomide promote the ubiquitination-mediated degradation of two essential transcription factors, IKZF1 (Ikaros) and IKZF3 (Aiolos), by directly recruiting them to CRBN, thereby inhibiting the proliferation of myeloma cells.